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Abstract
Background: Macaca mulatta is one of the most utilized non-human primate species in biomedical
research offering unique behavioral, neuroanatomical, and neurobiochemcial similarities to humans.
This makes it a unique organism to model various diseases such as psychiatric and
neurodegenerative illnesses while also providing insight into the complexities of the primate brain.
A major obstacle in utilizing rhesus monkey models for human disease is the paucity of protein
annotations for this species (~42,000 protein annotations) compared to 330,210 protein
annotations for humans. The lack of available information limits the use of rhesus monkey for
proteomic scale studies which rely heavily on database searches for protein identification. While
characterization of proteins of interest from Macaca mulatta using the standard database search
engines (e.g., MASCOT) can be accomplished, searches must be performed using a 'broad species
database' which does not provide optimal confidence in protein annotation. Therefore, it becomes
necessary to determine partial or complete amino acid sequences using either manual or
automated de novo peptide sequence analysis methods.
Results: The recently popularized MALDI-TOF-TOF mass spectrometer yields a complex MS/MS
fragmentation pattern difficult to characterize by manual de novo sequencing method on a
proteomics scale. Therefore, PEAKS assisted de novo sequencing was performed on nucleus
accumbens cytosolic proteins from Macaca mulatta. The most abundant peptide fragments 'b-ions
and y-ions', the less abundant peptide fragments 'a-ions' as well as the immonium ions were utilized
to develop confident and complete peptide sequences de novo from MS/MS spectra. The generated
sequences were used to perform homology searches to characterize the protein identification.
Conclusion: The current study validates a robust method to confidently characterize the proteins
from an incomplete sequence database of Macaca mulatta, using the PEAKS de novo sequencing
software, facilitating the use of this animal model in various neuroproteomics studies.
Background
Many species have been used to model various aspects of
human diseases including mental illness. However, the
complexity of human biochemistry, anatomy and behav-
ioral factors are not easily modeled in all species and war-
rant the use of species which have greater degrees of
functional equivalence for the measures under investiga-
tion. For example, the experimental use of Macaca mulatta
(rhesus monkey) has been essential for expanding our
knowledge of neurodevelopmental, neurodegenerative
and organic human brain diseases, as well as, for normal
brain function due in large part to close similarities in
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neuroanatomy, neurobiochemistry and behavior com-
pared with other species. Moreover, the use of Macaca
mulatta has significant translational value for understand-
ing the influence of alterations in gene and protein expres-
sion in human disease processes.
One potential obstacle to comprehensive assessments of
protein alterations is the relative paucity of available pro-
tein annotations for rhesus monkeys. Currently; NCBInr,
Swiss-Prot and TrEMBL list 330210, 14991 and 55805
human protein annotations, respectively. However,
NCBInr, Swiss-Prot and TrEMBL list only 41968, 297 and
1801 protein annotations for rhesus monkey, respec-
tively. The highly uncharacterized nature of the rhesus
monkey proteome makes it difficult to identify proteins,
demonstrate differential regulation of proteins and inves-
tigate their post-translational modifications. The charac-
terization of proteins of interest from rhesus monkey
using the standard database search engines (e.g., MAS-
COT) has a limitation in that 'broad species database'
searches are needed which results in less than optimal
protein annotation. This limitation can be overcome in
some respects using a de novo sequencing strategy, in
which partial or complete amino acid sequence informa-
tion is obtained using either manual or automated de novo
peptide sequence analysis. This approach has been suc-
cessfully utilized in recent studies to characterize peptides
bound to class I MHC molecule HLA-A2.1[1], human skin
elastin protein[2] and proteins from unsequenced
genome of Halorhodospira halophila[3].
While manual protein sequencing via Edman degradation
yields exact amino acid sequence without ambiguity, the
procedure is laborious and does not lend itself to high-
throughput analysis. It also lacks the sensitivity of mass
spectrometry and can be halted by the presence of blocked
amino acids. Fortunately, automated software tools have
been developed to characterize the amino acid sequences
generated from tandem mass spectrometry such as the
complex MS/MS fragmentation pattern generated by
MALDI-TOF-TOF mass spectrometer. Quality MS/MS
spectrum consists of a ladder for y-ions and b-ions peaks.
De novo sequencing uses the mass difference between two
adjacent ions to deduce the peptide fragment sequence.
However, factors such as incomplete fragmentation
(whereby not all the y- and b-ions are present in the spec-
trum), imprecise precursor ion selection due to overlap-
ping peptide fragment masses, low signal-to-noise ratio
and unpredicted post-translational modifications (PTMs)
complicate the manual de novo sequencing.  De novo
sequencing enables the analysis of quality MS/MS spectra
which fails to generate protein identification after data-
base searches, which is the case for the majority of pro-
teins in rhesus monkeys. In fact, de novo sequencing is the
only alternative for study of species with incomplete data-
bases and databases which are not in the public domain
[2,4-6]. Several strategies have been utilized more recently
for de novo sequencing including chemical derivatization
that add acidic, fixed charge or basic moieties[1,7-13].
These have included various derivatization protocols such
as sulfonation of the peptide N-terminal group. This deri-
vatization creates a strong acidic group which greatly
enhances fragmentation ability of tryptic peptides to pro-
duce b and y fragments. The use of 18O incorporation at
the C-terminus of peptides during protein hydrolysis has
also been applied [14,15]. The current study shows the
utility of underivatized peptides using MALDI-TOF-TOF.
To this end, de novo sequencing of peptides isolated from
cytosolic fractions of the ventral striatum of rhesus mon-
keys was performed. The ventral striatum/nucleus
accumbens is an integral component of the cortico-
straital-palldial-thalamic/mesencephalic circuit which is
involved in sensorimotor integration. Furthermore, dys-
regulation of the ventral striatum has been implicated in
a variety of psychiatric disorders, including substance
abuse [16,17], schizophrenia [18-20] and depression [21-
23]. The use of the ventral striatum tissue and the
cytosolic fraction from this region is based on the research
interests of our laboratory. However, the de novo sequenc-
ing strategy presented here is generalizable to all brain
regions, tissues and other protein preparations.
The presented method consists primarily of de novo
sequencing of underivatized peptides using the MALDI-
TOF-TOF, compared to various derivatizing strategies
used recently for various de novo studies. The generated
sequences were used to perform homology searches to
characterize the protein identification. The current study
validates a robust method to confidently characterize pro-
teins from an incomplete sequence database of Macaca
mulatta thereby facilitating the use of this animal model in
various neuroproteomics studies.
Results and discussion
Comparison of the rhesus monkey de novo sequences with
sequences in the human protein database enabled the val-
idation of the de novo capabilities of the present method.
This was accomplished by performing the detailed de novo
method on tandem mass spectrometer spectra from
Homo sapiens samples and objectively assessing the accu-
racy of the de novo sequencing by performing conven-
tional database search (MASCOT) on the same spectra.
Figure 1 shows the preliminary separation of proteins
from nucleus accumbens of Macaca mulatta using the two-
dimensional gel electrophoresis. The protein spots
selected for de novo sequencing analysis ranged between
11- to 70-KDa and pI of 4.5–6.5 with a uniform distribu-
tion over the entire 2-D gel with respect to the Mr and pI.
The labeled protein spots were subjected to in-gel trypsinBMC Genomics 2007, 8:270 http://www.biomedcentral.com/1471-2164/8/270
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digestion after de-staining the gel plugs. The peptide frag-
ments extracted from the gel plugs were then subjected to
tandem-mass spectrometry using the ABI 4700 proteom-
ics analyzer (MALDI-TOF-TOF).
Tandem-mass spectra were then submitted for database
searching (GPS Explorer: MASCOT), allowing to be
searched with and without all known post-translational
modifications, for protein characterization using the lim-
ited  Macaca mulatta database. The majority of spectral
analyses yielded no positive characterization, at which
point spectra were subjected to PEAKS de novo analysis.
According to the manufacturer, "the algorithm first com-
putes a y-ion matching score and a b-ion matching score
at each mass value according to the peaks around it. If
there are no peaks around a mass value, a penalty value is
assigned. The algorithm then efficiently computes many
amino acid sequences that maximize the total scores at the
mass values of b-ions and y-ions. These candidate
sequences are further evaluated by a more accurate scoring
function, which also considers other ion types such as
immonium ions and internal-cleavage ions (Figure 2).
The problem of ion absence is addressed because the
PEAKS model assigns a score (or penalty) for each mass
value. The software also computes a 'positional confi-
dence' for each amino acid in the final result by examining
the consensus of the top-scoring peptides" [4].
Thirteen targeted protein spots (Figure 1) were identified
by MALDI-TOF-TOF followed by peptide sequencing
using PEAKS Studio 4.0 de novo sequencing software. The
generalized schematic of the methodology used in the
current study to compile a database for Macaca mulatta is
depicted in Figure 3. Detailed information of the con-
Representative 2D gels of Macaca mulatta protein sample stained with SyproRuby™ Figure 1
Representative 2D gels of Macaca mulatta protein sample stained with SyproRuby™. The polypeptide molecular 
mass scale in kDa is depicted on the y-axis while the x-axis shows the pI range. The proteins were resolved in 4–7 linear pH 
gradient (Immobiline DryStrips; 240 × 3 × 0.5) and 8–15% gradient SDS-PAGE (2400 × 2000 × 1 mm). The results of the pro-
teins that were identified (indicated by arrows) by in-gel trypsin digestion and MALDI-TOF-TOF followed by de novo sequenc-
ing are elaborated in Table 1.
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firmed protein characterization are elaborated in Table 1
with respect to the precursor mass, m/z  error (ppm),
PEAKS and SPIDER score for confidence interval (%) for
the PEAKS de novo generated peptide sequences and their
corresponding homology searches. This method charac-
terized 13 protein spots out of 30 protein spots initially
selected for de novo analysis.
The tandem-mass spectra were analyzed by PEAKS de novo
sequencing software to generate amino acid sequences
(Figure 2). All tandem-mass spectra were deconvoluted to
minimize the error in de novo sequencing. Figure 2 shows
the fragmentation pattern of a precursor ion with m/z of
1967.8951. As has been documented previously and can
be noted in the spectrum (Figure 2), complementary
information is not always available for all b-ions and y-ions
and not all the immonium ions are represented in the
spectra. Spectral analysis is further complicated by the
appearance of some a-ions, neutral losses of water and
ammonia for b-ions  and  y-ions. These analysis caveats
render the ability to obtain a manual de novo sequence
tedious if not impossible. As elaborated in the Methods
Section, the PEAKS de novo sequencing utilizes most abun-
dant peptide fragments 'b-ions and y-ions'; the less abun-
dant peptide fragments 'a-ions'; the neutral losses of water
and ammonia for b-ions and y-ions; as well as the immo-
nium ions to develop confident and complete peptide
sequences de novo from MS/MS spectra[24]. The b-, y-, a-,
and immonium-ions as well as the neutral losses of water
and ammonia for y-ions are tabulated in Figure 2 for the
amino-acid sequence 'RSALQAAHDAVAQEGQCR'. The
tandem-mass spectrum in Figure 2 is representative of the
Representative De novo analysis of a MALDI-TOF-TOF spectrum Figure 2
Representative De novo analysis of a MALDI-TOF-TOF spectrum. (A) The x- and y-axes show the mass to charge 
(m/z) ratio and the % abundance of the precursor ion fragments, respectively. The MS/MS spectrum was analyzed by PEAKS de 
novo sequencing software to generate 'RSALQAAHDAVAQEGQCR'. (B) The table details peptide fragments 'b-ions, y-ions 
and a-ions' and the neutral losses of water and ammonia for b-ions and y-ions as well as the immonium ions to develop confident 
and complete peptide sequence de novo from MS/MS spectrum. (C) The SPIDER homology search of this peptide resulted in 
sequence from Ubiquitin carboxyl-terminal hydrolase isozyme L1 as 'NEAIQAAHDAVAQEGQCR'.
PEAKS De Novo sequence :    [RS] ALQAAHDAVAQEGQCR
SPIDER Homology search:      [NE] AIQAAHDAVAQEGQCR
Rank 1 Protein Description:
UBL1_HUMAN (P09936) Ubiquitin carboxyl-terminal hydrolase isozyme L1 
( score 10.0 ):
1 MQLKPMEINPEMLNKVLSRLGVAGQWRFVDVLGLEEESLGSVPAPACALLLLFPLTAQHE 60
61 NFRKKQIEELKGQEVSPKVYFMKQTIGNSCGTIGLIHAVANNQDKLGFEDGSVLKQFLSE 120
121 TEKMSPEDRAKCFEKNEAIQAAHDAVAQEGQCRVDDKVNFHFILFNNVDGHLYELDGRMP  180
181 FPVNHGASSEDTLLKDAAKVCREFTEREQGEVRFSAVALCKAA 223 
De novo + Homology Search
NEAIQAAHDAVAQEGQCR
A
B CBMC Genomics 2007, 8:270 http://www.biomedcentral.com/1471-2164/8/270
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similar analysis performed on the remaining protein spots
from Figure 1.
Twenty peptide sequences were characterized by PEAKS de
novo  sequence analysis software from 13 protein spots
(Table 1). The generated sequences were used to perform
homology searches to characterize proteins. As a standard
measure, all de novo generated amino-acid sequences were
searched further for homologous sequences using the
PEAKS homology search engine against the Mammalian
database. Out of the twenty de novo generated sequences
subjected to PEAKS homology search, thirteen yielded
positive protein characterization (Table 1). All peptide
sequences exhibited homology to Homo sapiens, with the
exception of the sequence from one spot (GST pi enzyme:
Macaca mulatta), The inability of the PEAKS homology
search to resolve the remaining seven sequences may be
attributed to the fact that the software assumes that the de
novo sequence is 100% correct. Whereas standard BLAST
assumes 100% accuracy of the de novo sequence, SPIDER
software accounts for possible errors in de novo sequenc-
ing. Also, it should be noted that the conventional search
engines such as BLAST and FASTA are designed to handle
queries which are longer than 35 amino acids. Prototypi-
cally, the peptide sequences obtained after trypsin diges-
tion are not longer than 10–15 amino acids. SPIDER
software was utilized for homology based database
searches in instances where PEAKS homology searches
failed to provide positive protein identification. Such
errors were characteristically due to partially correct
sequence tags and replacement of an amino acid segment
by another segment with approximately the same mass.
The criteria used for the SPIDER based searches were as
follows: non-gapped homology match; mass tolerance of
0.1 Da; NCBInr database; leucine equals isoleucine; lysine
equals glutamine; carbamidomethylation and methio-
nine in oxidized form. The approach yielded positive
characterization of the remaining seven peptide
sequences. Of these, five peptide sequences resulted in the
characterization of three new proteins previously not
characterized by the PEAKS homology search. The
remaining two peptides correspond to previously identi-
fied proteins; however, the peptides represent new charac-
terizations.
Table 1 also shows that the peptide sequences generated
by the PEAKS de novo sequencing software returned iden-
tical sequences when searched for homologous sequences
Schematic of the methodology for compilation of protein database for Macaca mulatta from De Novo analysis of MALDI-TOF- TOF spectra Figure 3
Schematic of the methodology for compilation of protein database for Macaca mulatta from De Novo analysis of MALDI-TOF-
TOF spectra.
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in the database, with the exception of four peptides
belonging to three proteins. Thus, the PEAKS de novo
sequencing software was able to provide positive protein
identification in most instances. An example of the added
benefit of coupling PEAKS de novo sequencing software
with the SPIDER homology search is shown in Figure 2.
The original sequence generated by the PEAKS de novo
software was '[RS]A [L]QAAHDAVAQEGQCR', whereas
the SPIDER homology search returned a sequence of
'[NE]A [I]QAAHDAVAQEGQCR' with a unequivocal
score of 10 and associated to protein ubiquitin carboxyl-
terminal esterase L1 (Homo Sapiens). At least a part of the
error of the PEAKS de novo software was due to the I/L
ambiguity.
Thirteen targeted protein spots (Figure 1) were identified
by MALDI-TOF-TOF followed by peptide sequencing
using PEAKS Studio 4.0 de novo sequencing software (e.g.
Figure 2). The generalized schematic of the methodology
used in the current study to compile a database for Macaca
mulatta is depicted in Figure 3. The detailed information
of the confirmed protein characterization are elaborated
in Table 1 with respect to the precursor mass, m/z error
(ppm), PEAKS and SPIDER score for confidence interval
(%) for the PEAKS de novo generated peptide sequences
and their corresponding homology searches. This method
characterized 13 protein spots out of 30 protein spots ini-
tially selected for de novo analysis.
Conclusion
Contemporary proteomics requires prompt and confident
protein identification of proteins of interest. The ability to
utilize animal models to study the biochemical correlates
of human disease requires a more complete database of
those species as a prerequisite. To this end, the de novo
sequencing strategy presented here provides a rapid and
reliable means to identify proteins in Macaca mulatta – a
species for which publicly available protein databases are
very limited. However, it is important to note that this
strategy is generalizable to other tissues, protein prepara-
tions and species and is not exclusive for Macaca mulatta
or for cytosolic protein fractions from brain.
From 30 excised gel spots 13 were identified by mass spec-
trometry coupled with PEAKS de novo analysis software.
Among the proteins were receptor-associated proteins,
proteins involved in intra-cellular signaling, cytoskeletal
structure, protein folding, hormonal changes and regula-
tion of oxidative stress. The current study was undertaken
to delineate a preliminary proteomics scale methodology
to identify proteins de novo from NAc cytosol in the pri-
mate brain. Following mass spectrometric analysis, the
most abundant peptides in the mixture led to the most
accurate protein identification – hence, less abundant
proteins may be overlooked. However, this caveat holds
for all two dimensional gel-based proteomic approaches
for studying disease states. Nevertheless, the present
Table 1: The proteins identified by de novo amino acid sequencing using MALDI-TOF-TOF
# Precursor ion (m/z) De novo peptide 
sequence
Homology search peptide sequence 
[PEAKS()/SPIDER(●)]
Score %() arbitrary(●) Sequence assigned to protein 
(Species)
1 1042.5265
1667.8766
LVTFYEDR
VPAFLSAAEVEEHLR
LVTFYEDR()
VPAFLSAAEVEEHLR()
97.81()
99()
Crystallin, mu (Homo Sapiens)
2 1631.7706 FQNIDFAEEVYTR FQNIDFAEEVYTR() 99() Guanine aminohydrolase(Homo 
Sapiens)
3 1303.7262 VLTPELYAELR
GTGGVDTAAVGGVFDV
SNADR
VLTPELYAELR()
GTGGVDTAAVGGVFDVSNADR (●)
99()
12.3(●)
Brain creatine kinase (Homo 
Sapiens)
4 1516.6975
1954.0564
[RT]YDESGPS[L]VHR
VAPEEHPVLLTEAPLNPK
[QE]YDESGPS[I]VHR(●)
VAPEEHPVLLTEAPLNPK(●)
7.6(●)
11.2(●)
Actin beta (Homo Sapiens)
5 1967.8951
1648.6646
[RS]A[L]QAAHDAVAQE
GQCR
[N]GHLYELDGR
[NE]A[I]QAAHDAVAQEGQCR(●)
[D]GHLYELDGR(●)
10.0(●)
5.8(●)
Ubiquitin carboxyl-terminal 
esterase L1 (Homo Sapiens)
6 1211.6733 Q [L]TVNDL[VP]GR
EGGLGPLNIPLLADVTR
Q[I]TVNDL[PV]GR(●)
EGGLGPLNIPLLADVTR()
5.6(●)
95.97()
Peroxiredoxin 2 isoform b (Homo 
Sapiens)
7 1684.9053
2560.2588
AAVEEGIVLGGGCALLR
LVQDVANNTNEEAGD
GTTTATVLAR
AAVEEGIVLGGGCALLR()
LVQDVANNTNEEAGDGTTTATVLAR()
98.28()
98.49()
Heat shock 60 kD protein 1 (Homo 
Sapiens)
8 1987.0314 AIAELGIYPAVDPLDSTSR AIAELGIYPAVDPLDSTSR(●) 11.2(●) ATP synthase beta chain, 
mitochondrial precursor (Homo 
Sapiens)
9 1917.9341 FQDGDLTLYQSNTFLR FQDGDLTLYQSNTFLR() 96.24() GST pi enzyme (Macaca mulatta)
10 1256.55 NCSETQYERK NCSETQYERK() 99.1() 14-3-3 gamma protein (Homo 
Sapiens)
11 1253.6162
1981.9982
FEELNADLFR
TVTNAVVTVPAYFNDSQ
R
FEELNADLFR()
TVTNAVVTVPAYFNDSQR()
97.95()
99.49()
Heat shock 70 kDa protein 8 
isoform 1(Homo Sapiens)
12 1917.9427 SIQEIQELDKDDESLR SIQEIQELDKDDESLR() 99.17() Rho GDI alpha (Homo Sapiens)
13 1337.7222 PPYTVVYFPVR PPYTVVYFPVR() 98.1() Glutathione S-transferaseBMC Genomics 2007, 8:270 http://www.biomedcentral.com/1471-2164/8/270
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results provide the first preliminary de novo proteomic
profile from Macaca mulatta and will form the basis of the
future proteomics scale studies using non-human pri-
mate.
Methods
Subjects and tissue
Four adult male rhesus monkeys (Macaca mulatta) were
restrained with Telazol, given intravenous heparin and
then an overdose of intravenous sodium pentobarbital.
After the confirmed absence of brain stem reflexes was
established, the monkeys were transcardially perfuse with
phosphate buffered saline to evacuate brain vasculature.
Brains were blocked using a rhesus monkey brain matrix
that allows 4 mm coronal blocks at various AP locations
(Electron Microscopy Sciences, Ft. Washington, PA).
Blocks were divided into their two component hemi-
spheres – one for fresh frozen sections at -80°C and the
other for dissection of blocks for paraffin embedding.
Brain tissue from these monkeys was frozen within 40
minutes of the time of death. All experiments were con-
ducted in accordance with the National Institutes for
Health Guide for the Care and Use of Laboratory Animals.
Protein isolation and fractionation
One hundred and fifty milligram punches were dissected
from NAc from each subject. A steel mortar and pestle
chilled in dry ice were used to pulverize the frozen brain
tissue from each subject separately into a dry homogenate
in the presence of liquid nitrogen. Tissue proteins from
each subject were fractionated into membrane, nuclear
and cytosolic fractions as described previously [25,26].
The tissues were homogenized in 10 mM HEPES, 10 mM
NaCl, 1 mM KH2PO4, 5 mM NaHCO3, 1 mM CaCl2, 0.5
mM MgCl2, 5 mM EDTA, 1 mM phenylmethylsulfonylflu-
oride, 10 mM benzamidine, 10 μg/ml aprotinin, 10 μg/ml
leupeptin, 1 μg/ml pepstatin. The tissue homogenate
from each subject was centrifuged using a swinging bucket
rotor (Beckman Coulter SW55Ti) at 5333 × g for 5 min.
The supernatant from each subject (cytosolic and crude
membrane fraction) was further centrifuged at 59,255 × g
for 30 min at 4°C and the cytosolic supernatant was
stored at -80°C.
SDS-Polyacrylamide Gel Electrophoresis (PAGE)
The protein quantitation for SDS-PAGE was accom-
plished using the bicinchoninic acid protein assay kit
(Pierce, Rockford, IL). Laemmli sample buffer was used to
achieve equivalent protein concentrations for all samples.
Thirty micrograms of protein from each sample was
heated to 95°C for 5 min and electrophoresed on 10%
Tris-HCl SDS-PAGE gels (BioRad). Gel fixation, staining
by Pro-Q®  Diamond phospho-protein stain and the
SyproRuby™ staining of the SDS-PAGE was completed as
described in detail for 2D-PAGE.
Extraction of proteins for 2D-PAGE
The cytosolic protein fraction from each subject was pre-
cipitated by 2-D clean-up kit (GE Healthcare) at 20°C
overnight, pelleted by centrifugation (12,000 × g for 5
min) then air-dried for 2 min. Next, pellets were dissolved
in re-hydration buffer [RB; 7 M urea, 2 M thiourea, 4% (w/
v) 3-[(3-cholamidopropyl) dimethylammonio]-1-pro-
pane-sulfonate. The protein solution in RB was supple-
mented with immobilized pH gradient buffer 2% and 2%
dithiothreitol (DTT) (10 mg/ml). The protein concentra-
tions were established by the urea and detergent compat-
ible 2D-Quant kit (Amersham Biosciences).
2D-PAGE
Two hundred microgram aliquots of cytosolic proteins
from each subject were diluted in 400 μl of RB and
increased to a final volume of 450 μl with destreak reagent
(GE Healthcare). Immobiline™ DryStrips (240 × 3 × 0.5
mm, pH 4–7 linear) were re-hydrated for 10 hr on an
Amersham Pharmacia Biotech IPGphor [27] followed by
sequential isoelectric focusing (IEF) of samples as follows:
100 V for 100 V-hr, at 500 V for 500 V-hr, at 1000 V for
1000 V-hr, at 4000 V for 4000 V-hr, at 8000 V for 13500
V-hr (gradient) and at 8000 V for 60,000 V-hr. Fifty μA
current was passed per strip maintaining the platform
temperature at 20°C. Next, strips were equilibrated by
adding a solution containing; 6 M urea, 1.5 M Tris-HCl,
pH 8.8, 30% (v/v) glycerol, 2% (w/v) SDS and 2% (w/v)
DTT and gentle rocking for 10 min, to reduce the disulfide
bonds. Next, a solution containing 6 M urea, 1.5 M Tris-
HCl, pH 8.8, 30% (v/v) glycerol, 2% (w/v) SDS and 2.5%
(w/v) iodoacetamide was added to block sulphydryl
groups.
After equilibration, the IPG strips were transferred to 2-D
slab gels using 0.6% agarose stacking gel. The proteins
were further separated on the basis of their molecular
weight on 12.5% SDS-PAGE (2400 × 2000 × 1 mm) at a
constant 4 W per gel until the dye front reached the end of
the gel using the Ettan Dalt II System (GE Healthcare, Pis-
cataway, NJ). Ten μl of the molecular mass marker (Amer-
sham Rainbow marker RPN 800) was loaded on 2 mm2
filter paper which was placed on the basic end of the IPG
strip [28,29]. To visualize the proteome from this specific
pH and mass range, gels were stained with Sypro Ruby™
stain overnight. The excess stain was removed by 10%
methanol, 6% glacial acetic acid for 20 minutes. Protein
spots of interest were subjected to MALDI-TOF-TOF [30].
In-gel trypsin digestion
Individual protein spots from the 2-D gels were excised
with 1.5 mm diameter gel cutter (The Gel Company, San
Francisco, CA) [31]. The gel spots were washed for 20
min, twice in 100 μl of solution of 50 mM ammonium
bicarbonate, 50% methanol (v/v) in distilled water andBMC Genomics 2007, 8:270 http://www.biomedcentral.com/1471-2164/8/270
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once in 75% acetonitrile in distilled water for 30 min or
until the gel plugs turned opaque. Twenty micrograms of
lyophilized trypsin (883 pmol; Promega, Madison, WI)
was reconstituted in 1 ml of 20 mM ammonium bicarbo-
nate and incubated for 15 min at 37°C. The gel fragments
were dried by vacuum centrifugation and then incubated
overnight with 10 μl (200 ng) of trypsin at 37°C. The
supernatant from trypsin digest was transferred to a low
retention 96-well plate. Peptides from the gel pieces were
sequentially extracted twice in 100 μl of extraction buffer
[50% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid
(TFA) in distilled water (DW)]. The original tryptic super-
natant and the supernatants from two sequential extrac-
tions were combined and dried in a vacuum centrifuge.
The dried peptides from each gel plug were dissolved in 5
μl of 50% (v/v) acetonitrile, 0.1% trifluoroacetic acid in
distilled water and 0.5 μl deposited on the stainless-steel
MALDI target plate. After drying, the spot residue was
mixed with 0.5 μl of 5 mg/ml of α-cyano-4-hydroxy-cin-
namic acid (CHCA; Sigma-Aldrich, St. Louis, MO) in 50%
(v/v) acetonitrile, 0.1% trifluoroacetic acid in distilled
water[32].
MALDI-TOF-TOF
Mass spectrometry analyses were performed using the
Applied Biosystems 4700 Proteomics Analyzer (MALDI-
TOF-TOF; Foster City, CA) in reflector mode for positive
ion detection. The laser wavelength and the repetition rate
were 355 nm and 200 Hz, respectively. All the MS spectra
resulted from accumulation of at least 2000 laser shots.
The peak detection criteria used were; minimum S/N of 8,
local noise window width mass/charge (m/z) of 200 and
minimum full-width half-maximum (bins) of 2.9. The
mass spectra were calibrated using the three trypsin auto
digest products: fragment 100–107 ([M + H]+ = 842.51
Da), fragment 90–99 ([M + H]+ = 1045.556 Da) and frag-
ment 50–69 ([M + H]+ = 2211.105 Da) [33]. A maximum
of the ten strongest precursor ions per sample were chosen
for tandem mass spectrometry (MS/MS) analysis. The fol-
lowing monoisotopic precursor selection were used for
the MS/MS: minimum S/N filter of 10, excluding the most
commonly observed peptide peaks for trypsin and kera-
tin, and excluding the precursors within 150 resolution.
In the TOF1 stage, all ions were accelerated to 1 kV under
conditions promoting metastable fragmentation. The
peak detection criteria used were; S/N of 8 and local noise
window width of 250 (m/z).
De novo sequencing
The PEAKS Studio 4.0 (Bioinformatics Solutions, Water-
loo, Ontario, Canada) de novo sequencing software was
used for automated de novo sequencing followed by man-
ual confirmation of most sequences generated. A parent-
and fragment-mass error tolerance of 0.08 u; trypsin as the
protease with one maximum missed cleavage allowed;
deconvolute the charge state in the spectra to generate a
spectra in which each monoisotopic peak becomes singly
charged; partial modification of cysteine (carbamidome-
thyl-cysteine) and methionine (oxidized), were used as
the de novo sequencing parameters. The most abundant
peptide fragments 'b-ions and y-ions'; the less abundant
peptide fragments 'a-ions'; the neutral losses of water and
ammonia for b-ions and y-ions; as well as the immonium
ions were utilized to develop confident and complete pep-
tide sequences de novo from MS/MS spectra [24]. Since the
Macaca mulatta has an incomplete protein database, the
sequences generated from each spectrum were used for
protein identification by sequence homology in the mam-
malian database using either the PEAKS or SPIDER soft-
ware (Software Protein Identifier). Therefore, the SPIDER
software was useful when the de novo sequencing gave par-
tially correct sequence tags and at instances where a seg-
ment of amino acids was replaced by another segment
with approximately same masses [Han, Y JBCB; (3) 2005;
697–716]. The algorithm used for determining the proba-
bility based scoring with a given mass spectrum is
described in detail by Ma B et al [24]. Protein identifica-
tion was confirmed by checking the protein mass and pI
accuracy [30].
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